Emergent BioSolutions Inc. (EBS)

NYSE: EBS · IEX Real-Time Price · USD
13.19
+0.27 (2.09%)
Jan 31, 2023, 4:00 PM EST - Market closed
2.09%
Market Cap 658.03M
Revenue (ttm) 1.51B
Net Income (ttm) 53.50M
Shares Out 49.89M
EPS (ttm) 0.78
PE Ratio 16.91
Forward PE 7.94
Dividend n/a
Ex-Dividend Date n/a
Volume 808,051
Open 13.00
Previous Close 12.92
Day's Range 13.00 - 13.40
52-Week Range 10.61 - 47.71
Beta 0.89
Analysts Buy
Price Target 31.11 (+135.86%)
Earnings Date Feb 23, 2023

About EBS

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat b... [Read more]

Sector Healthcare
IPO Date Nov 15, 2006
Employees 2,416
Stock Exchange NYSE
Ticker Symbol EBS
Full Company Profile

Financial Performance

In 2021, EBS's revenue was $1.79 billion, an increase of 15.26% compared to the previous year's $1.56 billion. Earnings were $230.90 million, a decrease of -24.32%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $31.11, which is an increase of 135.86% from the latest price.

Price Target
$31.11
(135.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce

Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.

3 weeks ago - Zacks Investment Research

Emergent BioSolutions to cut 5% of its workforce in reorganization effort

Emergent BioSolutions Inc. EBS, +9.80% is cutting 132 jobs, or approximately 5% of its workforce in a reorganization that the company says will sharpen its strategic focus on core businesses. The biot...

3 weeks ago - Market Watch

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a ma...

3 weeks ago - GlobeNewsWire

Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

1 month ago - Zacks Investment Research

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

GAITHERSBURG, Md., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Ne...

2 months ago - GlobeNewsWire

4 Toxic Stocks More So Hazardous Amid Volatile Times

Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a fe...

Other symbols: DZSITWKSWDC
2 months ago - Zacks Investment Research

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies Emergent partners with the Armed Forces Research...

2 months ago - GlobeNewsWire

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

2 months ago - Zacks Investment Research

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

3 months ago - Zacks Investment Research

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022.

3 months ago - GlobeNewsWire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company's adjuvanted s...

3 months ago - GlobeNewsWire

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst

These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.

Other symbols: CAPLLZBPRIMRGRSPNT
3 months ago - InvestorPlace

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial r...

3 months ago - GlobeNewsWire

Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral

Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

4 months ago - Zacks Investment Research

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofo...

4 months ago - GlobeNewsWire

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

5 months ago - Zacks Investment Research

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immu...

5 months ago - GlobeNewsWire

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

3 Top Monkeypox Stocks to Buy Right Now

With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat...

Other symbols: BVNRYDGX
5 months ago - InvestorPlace

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following in...

6 months ago - GlobeNewsWire

Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates

Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.

6 months ago - Zacks Investment Research

Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.

6 months ago - GlobeNewsWire